Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...
Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...
Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...
As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...
马萨诸塞州剑桥市 - 市值4.49亿美元、专注于脑健康治疗的生物制药公司Sage Therapeutics, Inc. (NASDAQ: SAGE )今日宣布,其首席医疗官Laura Gault博士将离职寻求新的发展机会。她的离职将于2025年3月21日生效。Gault博士自2022年11月加入公司以来,一直负责监督公司的产品管线开发。根据 InvestingPro ...
US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...
In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against other best small-cap growth stocks to buy now. On November 4, 2024, Nick Sheridan ...
JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating on the name. The price target accounts for peaks sales ...
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...